Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences has its registered office in Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.
Our common shares are listed for trading on the Nasdaq Market (LMNL).
The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the linkage and regulation of the inflammatory and metabolic response, and promotes fibrosis. Learn more.
OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1 is highly selective for 5 oxo ETE, one of the most powerful chemo attractants and activators of eosinophils. Learn more.
Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.